Despite the significant improvements in the field of oncological treatments in recent decades, and the advent of targeted therapies and immunotherapy, urothelial carcinoma of the bladder remains a highly heterogeneous and difficult-to-treat neoplasm with a poor prognosis.
In this context, owing to the new methods of genomic sequencing, numerous studies have analyzed the genetic features of muscle-invasive bladder cancer, providing a consensus set of molecular classes, to identify malignancies that may respond better to specific treatments (standard chemotherapy, immunotherapy, target therapy, local-regional treatment, or combinations) and improve the survival. The aim of the current review is to provide an overview of the current status of the molecular landscape of muscle-invasive bladder cancer, focusing our attention on therapeutic and prognostic implications in order to select the most effective and tailored therapeutic regimen for the individual patient.
Molecular diagnosis & therapy. 2023 Oct 24 [Epub ahead of print]
Nicole Conci, Elisa Tassinari, Valentina Tateo, Matteo Rosellini, Andrea Marchetti, Costantino Ricci, Francesco Chessa, Matteo Santoni, Enrique Grande, Veronica Mollica, Francesco Massari
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italy., Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Oncology Unit, Macerata Hospital, Macerata, Italy., Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italy. .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/37874465